Background and objective: Pirfenidone is an effective anti-fibrotic agent for idiopathic pulmonary fibrosis (IPF). Although adverse events (AE) sometimes prevent patients from continuing treatment, current dose adjustment guidance does not consider patient body size or weight (BW). The aim of this study was to evaluate the importance of pirfenidone dose adjustment by body surface area (BSA) or BW for preventing AE and permitting continuous treatment in patients with interstitial pneumonia (IP). Methods: Sixty-seven Japanese patients with IP including 46 patients with IPF treated with pirfenidone between 2009 and 2015 were retrospectively evaluated. Pirfenidone doses were adjusted by BSA or BW and were compared with clinical parameters. Results: Forty-two of 67 patients (62.7%) with IP showed AE, most commonly gastrointestinal symptoms (77.5%). Patients having AE received significantly higher adjusted doses of pirfenidone by both BSA and BW (P = 0.024 and P = 0.010, respectively), while unadjusted doses did not differ. BSA-adjusted dose discriminated patients with AE from those without (area under the curve = 0.666 at 1085 mg/m 2 ). Six of seven patients (85.7%) who discontinued pirfenidone due to AE took ≥1085 mg/m 2 of pirfenidone. In a subgroup with IPF, patients taking a medium dose (median: 876 median-1085 mg/m 2 ) showed a lower annual decline in % forced vital capacity than patients taking a lower dose (P = 0.025). Conclusion: BSA-adjusted pirfenidone dosing may be useful to prevent AE whilst achieving a long-term treatment effect in patients with IP.
INTRODUCTION
Idiopathic interstitial pneumonia (IP) is a lifethreatening lung disease, 1 and idiopathic pulmonary fibrosis (IPF), in particular, is a catastrophic IP which has attracted significant attention in terms of treatments with novel drugs. [1] [2] [3] [4] Pirfenidone 5-7 and nintedanib 8, 9 are novel medicines which can decrease the annual decline of forced vital capacity (FVC); however, these medicines are insufficient to prevent disease progression in many patients. Continuing these medications for a prolonged period without adverse events (AE) is key to changing the disease trajectory and effectively decreasing progression.
Although pirfenidone is considered a generally safe medicine, major AE include gastrointestinal discomfort and photosensitivity reactions. Gastrointestinal discomfort and other symptoms sometimes prevent patients 
SUMMARY AT A GLANCE
Patients with interstitial pneumonia (IP) and adverse effects received a significantly higher dose of pirfenidone adjusted by body surface area and body weight. In a subgroup of patients with idiopathic pulmonary fibrosis (IPF), a high/medium dose was associated with a lower decline in % forced vital capacity (FVC). Body size-adjusted dosing may be beneficial for the treatment of IP.
from continuing treatment with pirfenidone, even if this AE is not classed as severe. Clinical trials in patients with less severe disease showed that the rates of AE-related treatment discontinuation was 4.9-15%; 10, 11 however, in clinical practice, discontinuation rates due to AE have reached 15.3-29% [11] [12] [13] [14] in both Japan and other countries. Therefore, the rate of AErelated discontinuation of pirfenidone may increase in patients with more severe IP in clinical practice. Furthermore, continuing pirfenidone treatment is important to decrease the reduction of FVC and mortality rate, even in patients with progressive IPF despite treatment with pirfenidone. 15 The dose of pirfenidone has initially been set as 40 mg/kg/day 16, 17 for the treatment of IP. In a rodent model, 30 or 100 mg/kg/day of pirfenidone attenuated bleomycin-induced pulmonary fibrosis. 18 However, the precise relationship between pirfenidone dose and AE remains unclear, and a dose adjustment by body surface area (BSA) or body weight (BW) has not been fully studied in patients with IP.
In the present study, we evaluated the importance of dose adjustment of pirfenidone by BSA or BW for preventing AE and allowing continuous treatment in patients with IP including IPF. To the best of our knowledge, this is the first study to show the benefit of adjustment of pirfenidone dose based on patient BSA and BW.
METHODS

Study population
Sixty-seven patients with IP including 46 patients with IPF who were treated with pirfenidone at our hospital from 2009 to 2015 were enrolled and retrospectively studied. All patients with IPF met the 2011 IPF consensus criteria of the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT). 2 The study protocol was approved by the Ethical Committee of Hamamatsu University School of Medicine (approval number E16-156).
Data collection
Clinical data on sex, age, smoking history, symptoms and treatments as well as laboratory and pulmonary function test (PFT) results were obtained from the medical records. Disease severity was assessed using the gender, age and physiology (GAP) staging system 19 or the JRS severity staging system. 20 JRS severity staging includes the arterial partial pressure of oxygen (PaO 2 ) at rest and minimum arterial blood haemoglobin saturation (SpO 2 ) during a 6-min walk test (6MWT). 20 Treatment with pirfenidone and AE Pirfenidone was initially prescribed at 600 mg/day and then an additional 600 mg/day of pirfenidone was added fortnightly until the total dose reached 1800 mg/ day, unless AE became too severe to continue dose escalation. In the present study, the daily dose of pirfenidone was adjusted by BSA or BW. BSA was calculated using the Du Bois formula. AE severity was assessed by grading according to the Common Terminology Criteria for Adverse Events (CTCAE).
Statistical analysis
Comparisons of categorical data between the groups were performed using the chi-square test or Fisher's exact test. Continuous data were compared using the Mann-Whitney U-test. The separation performance of AE by dose of pirfenidone was evaluated using receiver operating characteristic (ROC) curve analysis. Comparison of data between groups was performed with the Tukey-Kramer test. Statistical analyses were performed using EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is based on R and R Commander (The R Foundation for Statistical Computing, Vienna, Austria). EZR was designed to add statistical functions that are frequently used in biostatistics. 21 All tests were two-sided, and statistical significance was defined as P < 0.05.
RESULTS
Clinical characteristics, laboratory and physiological data and treatment with pirfenidone
Clinical characteristics, laboratory and physiological data of study patients are shown in Table 1 . Median age was 70 years and the median observation period was 37 months. Among the 67 patients with IP, 46 had IPF. The remaining 21 patients had a variety of IP diagnoses, with details given in Appendix S1 (Supplementary Information). Lung function was moderately impaired (median %FVC and percent diffusion lung capacity for carbon monoxide (%DL CO ) were 59.0% and 44.8%, respectively), and 48 of 67 patients were classified in the more severe stages of the severity grading system of JRS 20 (patients in stages III and IV). Sixteen of the 67 patients had received treatment for their IP prior to receiving pirfenidone and most of these (15/16 patients) had been treated with steroids, with or without other immunosuppressants. The remaining patient had been treated with intravenous immunoglobulin alone prior to treatment with pirfenidone. Long-term oxygen had been previously prescribed in 15 patients (22.4%). The median administration period of pirfenidone was 11 months.
AE and BSA-or BW-adjusted dose of pirfenidone
With respect to early maintenance dose of pirfenidone among the 67 patients with IP, 2 patients were treated with 600 mg/day, 16 with 1200 mg/day and 49 with 1800 mg/day of pirfenidone. AE were reported in 42 of 67 patients (62.7%). Types of AE are summarized in Figure S1 (Supplementary Information). The most common AE were gastrointestinal symptoms (n = 31, 73.8%), anorexia (n = 24, 57.1%) as well as photosensitivity reaction and liver damage (n = 9, 21.4% and n = 7, 16.7%, respectively). Prophylactic medications against gastrointestinal AE were administered for 20 patients (details are given in Appendix S2, Supplementary Information). Although no patients showed CTCAE grade 3 or more gastrointestinal AE in the prophylactic group, significant reduction of gastrointestinal AE was not found compared with that in the nonprophylactic group (53% vs 66%, respectively).
Next, we sought to separate patients with any AE from those without AE by dose of pirfenidone ( Fig. 1 ). Daily doses of pirfenidone (mg) did not separate patients with AE from those without (Fig. 1A) . However, calculation of doses of pirfenidone by BSA (mg/m 2 ; Fig. 1B ) or by BW (mg/kg; Fig. 1C ) significantly separated patients with AE from those without (P = 0.024 and 0.010, respectively). Patients with AE tended to be older than those without AE (Table S1 , Supplementary Information). Other characteristics including diagnosis of IP, PFT, disease severity grade and preceding treatments were not significantly different between the groups (Table S1, Supplementary Information).
Next, to confirm the utility of pirfenidone dose for separation of patients with AE from those without, ROC analysis was performed. If the cut-off BSA-adjusted dose was defined as 1085 mg/m 2 , patients with AE could be separated from those without (area under the curve (AUC), 0.666; sensitivity, 54.8%; specificity, 72.0%; Fig. 2A) . If the cut-off BW-adjusted dose was defined as 29.6 mg/kg, patients with AE could be separated from those without (AUC, 0.668; sensitivity, 54.8%; specificity, 76.0%; Fig. 2B ). However, with the unadjusted dose of pirfenidone, AUC was as low as 0.550 when the cut-off dose was defined as 1800 mg (sensitivity, 76.2%; specificity, 32.0%; Fig. 2C) .
Seven of 67 patients (10.4%) discontinued pirfenidone because of AE. Details are given in Table S2 (Supplementary Information). Six of these seven patients were treated with 1800 mg of pirfenidone. Six of these seven were treated with BSA-adjusted 1085 mg/m 2 or more, and five of these seven patients were treated with BW-adjusted 29.6 mg/kg or more of pirfenidone.
Treatment effects and BSA-or BW-adjusted dose of pirfenidone Treatment effect of pirfenidone was evaluated in 23 patients with IPF who underwent PFT 12 months after starting pirfenidone therapy. In these 23 patients, 13 were treated with 1200 mg and 10 were treated with 1800 mg of pirfenidone.
Changes in %FVC (Δ%FVC) at 12 months in each group are shown in Figure 3 . A significant difference was not found between patients taking 1200 mg and those taking 1800 mg of pirfenidone (P = 0.229; Fig. 3A ). When patients were divided into two groups based on the median value of BW-adjusted dose of pirfenidone (23.8 mg/kg), Δ%FVC was not different between higher and lower dose pirfenidone groups (P = 1.00; Fig. S2A (Supplementary Information)) . However, when these patients were divided into two groups based on the median value of BSA-adjusted dose of pirfenidone (876 mg/m 2 ), the patients taking a higher dose of pirfenidone (≥876 mg/m 2 ) showed a lower decline in lung function (Δ%FVC) whereas patients taking a lower adjusted dose had significantly greater decline in %FVC over the 12 months (P = 0.020; Fig. 3B) .
The characteristics of patients with IPF taking a higher BSA-adjusted dose and a lower dose are compared in Table 2 . Although patients in the higher dose group were significantly younger and had achieved a longer distance in 6MWT, other parameters such as PFT, disease severity grade and preceding treatments were not significantly different between the groups.
Acute exacerbation of IPF occurred in 2 of these 23 patients (8.7%). When the higher dose group was divided into two further groups based on the BSAadjusted cut-off dose for the detection of AE (1085 mg/m 2 ; Fig. 2A ), the median BSA-adjusted dose (876-1085 mg/m 2 ) group showed a significantly lower decline in lung function, measured by Δ%FVC, after 12 months than the lower dose group (P = 0.025; Fig. 3C ). However, in the same way, Δ%FVC in the BW-adjusted median-dose (23.8-29.6 mg/kg) and 
DISCUSSION
The present study was conducted to determine the importance of pirfenidone dose adjustment by BSA or BW for preventing AE and promoting continued treatment with pirfenidone. We found that patients with IP who had AE had received a significantly higher adjusted dose of pirfenidone by both BSA and BW, although the unadjusted dose did not differ. Furthermore, regarding treatment effects, IPF patients taking a higher (≥876 mg/m 2 ) or medium (876-1085 mg/m 2 ) dose had a lower decline in %FVC in 12 months than patients taking a lower dose.
Pirfenidone is a novel therapeutic agent which can decrease the annual decline of FVC in patients with IPF. [5] [6] [7] Although the treatment effect of pirfenidone is insufficient to prevent disease progression of IPF, it is effective even in patients with severely impaired pulmonary function. 22, 23 Furthermore, continued treatment with pirfenidone following an initial decline in %FVC could also decrease the subsequent decline of FVC and mortality. 15 However, in the same way, AE are commonly reported following pirfenidone treatment in patients in advanced stages of IPF and can sometimes lead to treatment discontinuation. 24 Notably, once gastrointestinal AE occur, many patients decline continuing treatment because of an aversion to pirfenidone in clinical practice. Thus, preventing AE is important to Figure 1 Initial administered dose of pirfenidone in patients with and without adverse events (AE). Initial doses of pirfenidone were compared between the groups. Unadjusted daily doses (mg) of pirfenidone could not separate patients with AE from those without (A). However, adjusted doses of pirfenidone by body surface area (BSA) (B) or by body weight (BW) (C) significantly separated patients with AE from those without (P = 0.377, 0.024 and 0.010, respectively). , patients with AE could be separated from those without (area under the curve (AUC), 0.666; sensitivity, 54.8%; specificity, 72.0%) (A). If the cut-off body weight (BW)-adjusted dose was defined as 29.6 mg/kg, patients with AE could be separated from those without (AUC, 0.668; sensitivity, 54.8%; specificity, 76.0%) (B). In the unadjusted dose of pirfenidone, AUC was 0.550 when the cut-off dose was defined as 1800 mg (sensitivity, 76.2%; specificity, 32.0%) (C).
ensure treatment continuation for prolonged periods, especially in advanced stages of IPF. Although prophylactic medications such as proton pump inhibitors for gastrointestinal AE were reportedly effective for longterm intake of pirfenidone, 12 these medications were not enough to prevent gastrointestinal AE in the present study. Regarding administered dose of pirfenidone, 1200 mg (low dose) of pirfenidone has been shown to decrease the decline in vital capacity to the same extent as 1800 mg (high dose) in Japanese patients with Figure 3 Treatment effects and administered doses of pirfenidone. Treatment effect of pirfenidone was evaluated in 23 patients with idiopathic pulmonary fibrosis (IPF) who underwent pulmonary function tests 12 months after starting pirfenidone therapy. Changes in % forced vital capacity (Δ%FVC) at 12 months in each group are shown. A significant difference was not found between patients taking 1200 mg and those taking 1800 mg of pirfenidone (P = 0.229) (A). When these patients were divided into two groups based on the median value of body surface area (BSA)-adjusted dose of pirfenidone (876 mg/m 2 ), Δ%FVC in patients taking higher doses was significantly higher than in patients taking lower doses (P = 0.020) (B). When the higher-dose group was further divided into two groups based on the BSA-adjusted cut-off dose for the detection of adverse event (AE; ≥1085 mg/m IPF. 6, 25 Therefore, lower doses of pirfenidone may reduce pirfenidone-related AE and ensure continuous and effective treatment, even in patients with advanced IPF, although the precise dose adjustment strategy for pirfenidone has not yet been established.
In an earlier study, the plasma concentration of pirfenidone did not predict AE or therapeutic effects. 17 Thus, an alternative method to predict these parameters in clinical practice is required. In a rodent model, 30 or 100 mg/kg/day of pirfenidone attenuated bleomycin-induced pulmonary fibrosis. 18 In clinical trials, the dose of pirfenidone was set as 40 mg/kg/day in early studies, 16, 17 thereafter being set at 2403 or 1197 mg/day in western countries 7, 26 and 1800 or 1200 mg/day in Japanese studies. 5, 6 However, precise dose adjustment based on patients' body size was not performed in these trials.
In the present study, a significantly higher BSA-or BW-adjusted dose was found in patients with AE, and most patients who discontinued pirfenidone had received a higher dose of pirfenidone (1085 and 29.6 mg/kg or more, by ROC curve analysis). In addition, a BSA-adjusted medium dose of pirfenidone (876-1085 mg/m 2 ) significantly reduced the annual decline in %FVC, although the unadjusted dose did not. Therefore, the BSA-or BW-adjusted dose of pirfenidone, especially the BSA-adjusted dose, may be useful for the prediction of pirfenidone-associated AE and treatment effects. According to the studies using rodent models, concentrations of pirfenidone and its metabolites, 5-hydroxypirfenidone and 5-carboxypirfenidone which also have anti-fibrotic effects, reached a peak in lungs at 45 min after oral administration. 27 However, the concentrations in liver, kidneys and plasma were 2-4 times higher than that in lungs. 27, 28 Therefore, these results suggest that AE of pirfenidone occur more readily compared with treatment effects on lung fibrosis and the distribution of pirfenidone in the lung tissue of IPF may be important for treatment effects. 27 Not only dose adjustment but also the evaluation for organ/tissue distribution of pirfenidone may be important to keep balance between treatment effects and AE.
Our study has a number of limitations. First, the number of patients with IP who were administrated pirfenidone was relatively small. Second, this study was retrospectively conducted. Third, pirfenidone prescription was open-labelled. Finally, the plasma concentration of pirfenidone was not evaluated in this study, although this parameter was unable to predict AE or therapeutic effects in a previous study. 17 Pirfenidone concentration in several organs, including lung and gastrointestinal organs, may be related to therapeutic effects and AE as mentioned above. Further studies are required to evaluate concentrations of pirfenidone for effective therapy.
In conclusion, we found that patients with IP who reported AE had received a significantly higher adjusted dose of pirfenidone. Higher BSA-or BWadjusted doses were observed in the majority of patients who discontinued pirfenidone treatment. IPF patients taking higher doses (median: ≥876 mg/m 2 ), and especially medium doses (876-1085 mg/m 2 ), showed a lower annual decline in %FVC than patients taking lower doses. Taken together, body size-adjusted pirfenidone dosing regimens may be useful, especially BSA-adjusted dosing of 876-1085 mg/m 2 , to prevent AE and achieve a long-term and effective treatment strategy for IPF. fibrosis.
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